On this page

What happened

FDA posted a SUPPLX voluntary recall notice on September 4, 2026, following the company’s September 3 announcement. Testing identified undeclared yohimbine in Business Pill and Branch Manager for Men, with the notice describing dangerously high levels. The recall covered all lots and expiration dates of those two products distributed from September 16, 2023 through June 11, 2026. It did not cover every SUPPLX product or constitute a new clinical trial of yohimbine.

Why it matters

An undeclared pharmacologically active ingredient prevents buyers from assessing what they are taking. The notice warned that yohimbine can affect heart rate and blood pressure and may interact with other medicines or stimulants. This makes the finding relevant to products sold with performance-oriented positioning, even though the recall did not establish any cognitive benefit. Ingredient transparency and measured composition are separate requirements from a claim that a product supports focus or energy.

Scope and limitations

The company instructed consumers to stop using and dispose of the recalled products and to contact a healthcare provider about related adverse effects. The official notice supplies the product identifiers and consumer contact information. This article does not estimate an unreported injury count, infer that every product containing declared yohimbine has the same risk, or establish sales in Turkey. FDA’s publication of a company announcement is also not an endorsement of that company’s products. The scope is the named products and recall period.

This sourced news summary and translation were prepared with AI assistance. Source links, the news date and research limitations are disclosed; this is not a claim of independent medical expert review. News production method.

Sources

Research news is not medical advice or a recommendation to use a substance. Read findings in the context of the study design, participants and limitations. Editorial standards.

← All news